Sorry, you need to enable JavaScript to visit this website.

Efficacy and safety of tofacitinib in young patients aged 2 to less than 18 years with polyarticular course Juvenile Idiopathic Arthritis (JIA)

Efficacy, Safety, and Tolerability of Tofacitinib for Treatment of Polyarticular Course Juvenile Idiopathic Arthritis (JIA) in Children and Adolescent Subjects

Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT02592434
Protocol ID: A3921104
    Share
PrintDownload
Open Plain Language Summary Result: Click here